TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19217337

Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 15785941

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (Calcijex) administered as a bolus injection three times a week for up to 12 weeks, with initial doses of 0.5-1.5 microg based on severity of secondary HPT.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo administered three times a week for up to 12 weeks.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (Calcijex)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12151929

Group type: EXPERIMENTAL
Intervention: TA 50 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TA 100 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TA 10 mg/kg over 15 min with 1 mg x kg(‐1) x hr(‐1) maintenance infusion for 10 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simulation of previous studies with a 30‐min loading dose of 12.5 mg/kg and maintenance infusion of 6.5 mg x kg(‐1) x hr(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simulation of previous studies with a 30 mg/kg loading dose plus 16 mg x kg(‐1) x h(‐1) continuous infusion
Number of subjects: 30
Study: 10412096

Group type: EXPERIMENTAL
Intervention: WHP intervention (multiple risk factor intervention targeting smoking, nutrition, and physical activity)
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2055
Study: 7729044

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oxandralone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2029831

Group type: EXPERIMENTAL
Intervention: Triazolam 0.250 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6265109

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (500 mg/m2 I.V.), Adriamycin (50 mg/m2 I.V.), DTIC (250 mg/m2 I.V.), and vincristine (1 mg/m2 I.V.) every 4 weeks for three cycles followed by the same combination every 4 weeks for an additional six cycles.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Non-cross-resistant drug combination of BCNU (100 mg/m2 I.V.), procarbazine (100 mg/m2 p.o. daily x 10 days), methotrexate (25 mg/m2 I.V.), and vinblastine (5 mg/m2 I.V.) every 4 weeks for six cycles.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Alternating treatments with the two regimens for a total of six cycles of therapy.
Number of subjects: 202
Study: 31544471

Group type: EXPERIMENTAL
Intervention: Empirical intravenous vancomycin
Number of subjects: 6553
Study: 31084291

Group type: EXPERIMENTAL
Intervention: NAVIGATE (early intervention treatment model)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 404
Study: 28778815

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg/day for 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26372945

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 25
Study: 23598371

Group type: EXPERIMENTAL
Intervention: 16 mg candesartan in the first week, and 32 mg candesartan in the second and third week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21860000

Group type: EXPERIMENTAL
Intervention: CRT + EPO
Number of subjects: 257

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 257
Study: 19469696

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 93

Group type: COMPARATOR
Intervention: paliperidone ER
Number of subjects: 93

Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 93
Study: 17925885

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15514875

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) combined with maxillary protraction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maxillary protraction alone
Number of subjects: 20
Study: 11683079

Group type: EXPERIMENTAL
Intervention: Wearing a noseclip
Number of subjects: 13

Group type: COMPARATOR
Intervention: Without wearing a noseclip
Number of subjects: 13
Study: 9585306

Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Midazolam 0.08 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg/kg
Number of subjects: 600
Study: 8029790

Group type: COMPARATOR
Intervention: Low dose aspirin (A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity oral anticoagulation with warfarin (W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment with warfarin and aspirin (WA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (WA), Warfarin (W), Aspirin (A)
Number of subjects: 0
Study: 2644695

Group type: EXPERIMENTAL
Intervention: Silicone gravity drains
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVC drains (with vacuum suction)
Number of subjects: 0
Study: 47417

Group type: EXPERIMENTAL
Intervention: RA27/3 (intranasally)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HPV77.DE‐5
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vaccinees (combined)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Naturally infected patients
Number of subjects: 49
Study: 31079555

Group type: EXPERIMENTAL
Intervention: α-hydroxyisocaproic acid (α-HICA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate free acid (HMB-FA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: calcium β-hydroxy-β-methylbutyrate (HMB-Ca)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 40
Study: 28434043

Group type: EXPERIMENTAL
Intervention: Early whole brain radiotherapy (WBRT) (45 Gy)
Number of subjects: 318

Group type: COMPARATOR
Intervention: No early WBRT
Number of subjects: 318
Study: 25414065

Group type: EXPERIMENTAL
Intervention: Three-Dimensional Laparoscopic Vision System (3D LVS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Two-Dimensional Laparoscopic Vision System (2D LVS)
Number of subjects: 24
Study: 23618425

Group type: EXPERIMENTAL
Intervention: Computer reminders (ComRem) with general implementation activities (GIA)
Number of subjects: 286

Group type: COMPARATOR
Intervention: General implementation activities (GIA) only
Number of subjects: 286
Study: 21668835

Group type: EXPERIMENTAL
Intervention: 4% nicotinamide-phosphatidylcholine (N-PHCL) emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% topical clindamycin phosphate
Number of subjects: 0
Study: 19555037

Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (IL‐6) levels
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (TNF‐alpha) levels
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Repeated angioplasty
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Predilation before stenting
Number of subjects: 68
Study: 17004893

Group type: EXPERIMENTAL
Intervention: B. polyfermenticus tablets at a dose of 3.1 x 10(8) colony-forming units/day for 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: B. polyfermenticus tablets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12967736

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 10493339

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS (224 mmol/l)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/l)
Number of subjects: 738
Study: 8719029

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2066768

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg oral dextroamphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6354828

Group type: EXPERIMENTAL
Intervention: 30 mg of oral omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 mg of oral omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 90 mg of oral omeprazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30144099

Group type: EXPERIMENTAL
Intervention: Vixotrigine (400 mg for men, 300 mg for women) administered orally twice daily for 36 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered orally twice daily for 36 days
Number of subjects: 60
Study: 28410367

Group type: EXPERIMENTAL
Intervention: NO‐charged catheters
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NO‐charged urinary catheters
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular control catheters (CT‐group)
Number of subjects: 12
Study: 25937157

Group type: EXPERIMENTAL
Intervention: Cold knife conization with lateral hemostatic sutures
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cold knife conization without lateral hemostatic sutures
Number of subjects: 102
Study: 24345329

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21986094

Group type: EXPERIMENTAL
Intervention: s.c. denosumab (120 mg) every 4 weeks
Number of subjects: 5723

Group type: COMPARATOR
Intervention: i.v. zoledronic acid (4 mg) every 4 weeks
Number of subjects: 5723
Study: 19995510

Group type: EXPERIMENTAL
Intervention: Group II: bevelling the margins of buccal fissures (0.5 mm bevel) after enameloplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group I: without bevel (standard procedure)
Number of subjects: 20
Study: 18159148

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily
Number of subjects: 101
Study: 15528287

Group type: EXPERIMENTAL
Intervention: Video‐taped final year student doctor interviews
Number of subjects: 60

Group type: COMPARATOR
Intervention: Previous experience of a real student doctor interview
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maternal and child characteristics
Number of subjects: 60
Study: 11345495

Group type: EXPERIMENTAL
Intervention: Microsoft computer mouse with standard settings
Number of subjects: 12
Study: 11770784

Group type: EXPERIMENTAL
Intervention: Visual feedback during acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory feedback during acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined visual and auditory information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructing participants to attend to one information source
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Error detection and correction processes
Number of subjects: 0
Study: 9278661

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (46 Gy) and bolus 5-fluorouracil (30 min before six radiotherapy fractions)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Surgery combined with postoperative radiotherapy and 5-fluorouracil
Number of subjects: 136

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 136
Study: 8340736

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg and calcium 1000 mg daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Calcium 1000 mg daily
Number of subjects: 54
Study: 3089195

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) for three days before and during radiotherapy (five fractions of 400 rad [4 Gy] each)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) feeding recommenced 24 hours postoperatively via a feeding jejunostomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED)
Number of subjects: 20
Study: 29144103

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program including controlled breathing training, NMES superimposed onto voluntary muscular contraction for 8 weeks (2 h/week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 36
Study: 27617832

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 103
Study: 24915066

Group type: EXPERIMENTAL
Intervention: Active acupoint acupuncture for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inactive acupoint acupuncture for 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Active and Inactive acupoint)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active acupoint group
Number of subjects: 80
Study: 23259263

Group type: EXPERIMENTAL
Intervention: Acupuncture at Yuji (LU 10), needle inserted 20-35 mm in depth, retained for 60 min, rotated every 5 min
Number of subjects: 577

Group type: COMPARATOR
Intervention: Salbutamol aerosol, 200 microg, less than 8 sprays in 24 h
Number of subjects: 577
Study: 20009958

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment plus self-care
Number of subjects: 267

Group type: COMPARATOR
Intervention: Self-care alone (Control)
Number of subjects: 267
Study: 18486419

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 87
Study: 16682850

Group type: EXPERIMENTAL
Intervention: Bulimic Investigatory Test, Edinburgh (BITE)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Symptom Scale of BITE
Number of subjects: 995
Study: 12775312

Group type: EXPERIMENTAL
Intervention: Glutamate infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study: 10503800

Group type: EXPERIMENTAL
Intervention: Data monitoring committee with formal analyses every 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common statistical monitoring guidelines
Number of subjects: 0
Study: 8921129

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 86

Group type: COMPARATOR
Intervention: D&C (Dilatation and curettage)
Number of subjects: 86
Study: 1841669

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propanolol 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31584525

Group type: EXPERIMENTAL
Intervention: Intralesional ozone gas
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intralesional saline injection
Number of subjects: 74
Study: 29454336

Group type: EXPERIMENTAL
Intervention: Change in physical activity level (measured by the self-report Physical Activity Scale for the Elderly (PASE))
Number of subjects: 514
Study: 26328787

Group type: EXPERIMENTAL
Intervention: Morphine + Vecuronium
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 24849043

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone (0.5 mg) followed by buspirone (10 mg) tablet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Combination tablet of testosterone and buspirone
Number of subjects: 13
Study: 23110701

Group type: EXPERIMENTAL
Intervention: Posterior preperitoneal approach (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional anterior tension‐free repair (Group B)
Number of subjects: 120
Study: 20209619

Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1813
Study: 18611975

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 10

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 10
Study: 16967791

Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Catheter (PAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 14597456

Group type: EXPERIMENTAL
Intervention: Leech therapy (4 to 6 locally applied leeches)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Topical diclofenac therapy (28-day regimen)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Leech therapy
Number of subjects: 51
Study: 10748449

Group type: EXPERIMENTAL
Intervention: Pretherapeutic hyperprolactinemia (PRL >/=15.0 ng/mL)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Pretherapeutic PRL levels
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PRL mRNA expression
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PRLR positivity by ligand binding assay
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intermediate form of PRLR mRNA
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Long form of PRLR mRNA
Number of subjects: 99
Study: 9026624

Group type: EXPERIMENTAL
Intervention: Exposure to dusts and solvent vapours
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Short period of employment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Long period of employment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Duration of exposure
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: First period of exposure
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Longer period of exposure
Number of subjects: 146
Study: 1551541

Group type: EXPERIMENTAL
Intervention: Lecithin supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3891189

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 gm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide gel (30 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31050156

Group type: EXPERIMENTAL
Intervention: Glucose-lowering intervention
Number of subjects: 6826

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering intervention
Number of subjects: 6826

Group type: COMPARATOR
Intervention: Low 1,5-AG level (<39.7 μmol/L)
Number of subjects: 6826

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 6826
Study: 29342453

Group type: EXPERIMENTAL
Intervention: True air purifiers
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 55
Study: 26614591

Group type: COMPARATOR
Intervention: Sporting Qigong (SQG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Non-Sporting Qigong (NSQG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study: 24155118

Group type: EXPERIMENTAL
Intervention: Back Squat
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Power Clean
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 13
Study: 22819848

Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matched healthy control group
Number of subjects: 32
Study: 21171757

Group type: EXPERIMENTAL
Intervention: Serotonin depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18442449

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 microg once daily
Number of subjects: 302

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 302
Study: 16186434

Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/1 mg E2
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 12013355

Group type: EXPERIMENTAL
Intervention: Piperacillin 4.0 g-tazobactam 0.5 g administered every 8 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piperacillin 3.0 g-tazobactam 0.375 g administered every 6 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piperacillin 3.0 g-tazobactam 0.375 g every 4 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piperacillin 4.0 g-tazobactam 0.5 g every 6 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous-infusion piperacillin 12 g-tazobactam 1.5 g/day
Number of subjects: 12
Study: 10202313

Group type: EXPERIMENTAL
Intervention: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In after bronchial provocation with allergen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In (control measurement)
Number of subjects: 9
Study: 8636519

Group type: EXPERIMENTAL
Intervention: Ventilation at six different values of expiratory time (TE) with constant tidal volume and total breath duration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Addition of end-inspiratory pause (EIP)
Number of subjects: 9
Study: 2281671

Group type: EXPERIMENTAL
Intervention: anxiolytic drug
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 444024

Group type: EXPERIMENTAL
Intervention: Brief hospitalization followed by the availability of transitional day care
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Brief hospitalization
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard inpatient care
Number of subjects: 175
Study: 31109349

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 100
Study: 28074798

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 200
Study: 26156269

Group type: EXPERIMENTAL
Intervention: Local anesthetic administration with vibration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Injections without the use of vibration
Number of subjects: 30